TRANSHEMO: Determinants and Consequences of the Transition to Adulthood Among Adolescents With Haemophilia

Sponsor
Assistance Publique Hopitaux De Marseille (Other)
Overall Status
Unknown status
CT.gov ID
NCT02866526
Collaborator
(none)
380
29
33.5
13.1
0.4

Study Details

Study Description

Brief Summary

Severe haemophilia is a rare disease characterized by spontaneous bleedings from early childhood, which may lead to various complications especially in joints. Due to advances in medical care and more specifically in the development of prophylactic strategies by the application of clotting factor concentrates, life expectancy of persons with severe haemophilia has significantly increased over the last decades. This progress requires a long-term follow-up, including into adulthood. The adherence to a regular clinical follow-up and to a prophylactic treatment then depends on how successful patients' transition from childhood to adulthood has been as this process involves a transfer of responsibility from parents to patients concerning the management of their health. Beyond the issue of patients' adherence, a suboptimal transition may also impair quality of life and the entry into adulthood, especially at the social, emotional and professional levels. Only a few studies have been conducted to identify the specific needs and difficulties young persons with severe haemophilia experience during their transition from childhood to adulthood, and none of these studies has been carried out in France where the features of the health care system are very specific.

Therefore, this study aims to address the issue of transition into adulthood among young persons with severe haemophilia in France. This study will focus not only on the facilitators and barriers of the access to health care but also, from a more global perspective, on all the specific concerns and difficulties they may experience as they grow into adulthood which may impair their long-term health related quality of life as well as their personal empowerment. This study will also allow to identify some of the socio- cognitive, emotional, and familial determinants of a good transition into adulthood.

Condition or Disease Intervention/Treatment Phase
  • Other: Patient questionnaire

Detailed Description

The main objective of this study is to assess the impact of transition from adolescence into adulthood especially on adherence to health care, among young people with severe haemophilia in France.

The operational objectives of this study are: i) to compare the level of adherence in adolescents and in young adults (YA) ii) to identify determinants (medical, organisational, socio-demographic and social, and psychosocial and behavioural factors) of the level of adherence in YPWH (young people with haemophilia), iii) to assess specific factors involved in suboptimal level of adherence in the sub-groups of adolescents on one hand and of YA on the other hand, iv) to identify groups of patients (clusters) regarding both their level of adherence and their psychosocial characteristics, v) to examine trough a qualitative approach YPWH needs and expectations towards the health care system during the transition process, and to identify some ways to improve their global care.

This study is an exploratory, observational, multicentric, transversal study aimed at describing the perceptions of adolescents (14-17 years old) with severe haemophilia to those of young adults (20-29 years old) regarding their expectations and their feelings about growing into adulthood. Every patient enrolled in the FranceCoag national cohort (cohort of French patients suffering from inherited deficiencies of coagulation proteins), suffering from severe haemophilia, aged from 14 to 17 years old or from 20 to 29 years old, will be offered to get enrolled in the TRANSHEMO study (expected number eligible of participants: 154 adolescents and 389 young adults). , among whom 70% are expected to take part in the study). The patients' participation in this study will not modify their medical or paramedical care. A multifocal approach which combines both quantitative and qualitative data collection will be proposed.

Study Design

Study Type:
Observational
Anticipated Enrollment :
380 participants
Observational Model:
Other
Time Perspective:
Cross-Sectional
Official Title:
Determinants and Consequences of the Transition to Adulthood Among Adolescents With Haemophilia - TRANSHEMO
Actual Study Start Date :
Feb 13, 2017
Anticipated Primary Completion Date :
Jun 1, 2019
Anticipated Study Completion Date :
Dec 1, 2019

Arms and Interventions

Arm Intervention/Treatment
group1

adolescents (14-17 years old)

Other: Patient questionnaire
quantitative and qualitative data collection will be proposed.

group 2

young adults (20-29 years old)

Other: Patient questionnaire
quantitative and qualitative data collection will be proposed.

Outcome Measures

Primary Outcome Measures

  1. Number of follow-up visits / theoretical number of follow-up visits over the last two years [Two years]

    Adherence to clinical follow-up

  2. Number of injections of prophylactic treatment realized / theoretical number of injections of prophylactic treatment over the last three months [3 months]

    Adherence to prophylactic treatment

Secondary Outcome Measures

  1. Patient-reported adherence [one day]

    Specific item of the patient questionnaire (0-10 points)

  2. Physician-reported adherence of the patient [one day]

    Specific item of the medical questionnaire (0-10 points)

  3. Number of haemorrhagic events [one day]

    Specific item of the medical questionnaire

Eligibility Criteria

Criteria

Ages Eligible for Study:
14 Years to 29 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients with severe haemophilia

  • Patients enrolled in the FranceCoag national cohort

  • Patients aged from 14 to 17 years old (adolescents group) or from 20 to 29 years old (young adults group)

  • Adults patients having given their agreement to participate in the study, or minor patients authorized to participate in the study by their parents or their legal representatives

Exclusion Criteria:
  • Patients with comprehension problems

  • Patients unable to read or to write

  • Adults patients not having given their agreement to participate in the study, or minor patients unauthorized to participate in the study by their parents or their legal representatives

Contacts and Locations

Locations

Site City State Country Postal Code
1 CHU D'Amiens Amiens France 80054
2 CHU de Besançon Besançon France 25020
3 CHU Bordeaux Bordeaux France 33076
4 Chu Brest Brest France 29609
5 CHU CAEN Caen France 14033
6 Ch Chambery Chambéry France 73011
7 Chu Clermont-Ferrand Clermont-Ferrand France 63003
8 Chu Dijon Dijon France 21034
9 CHU Grenoble Grenoble France 38043
10 CH Versailles/ Le Chesnay Le Chesnay France 78157
11 Chu Lille Lille France 59037
12 CHU Limoges Limoges France 87000
13 Hospices Civiles de Lyon Lyon France 69677
14 Assistance Publique Hôpitaux de Marseille Hôpital de la Timone Marseille France 13354
15 CH Montmorency Montmorency France 95160
16 CHU Montpellier Montpellier France 34295
17 CHU Nancy Nancy France 54511
18 CHU Nantes Nantes France 44093
19 CHU Nice Nice France 06202
20 Assistance Publique Hôpitaux de Paris Paris France 75015
21 Assistance Publique Hôpitaux de Paris Paris France 94275
22 CHU Reims Reims France 51092
23 CHU Rennes Rennes France 35000
24 Chu Rouen Rouen France 76031
25 CHU Réunion Saint-Denis France 97405
26 CHU Saint-Etienne Saint-Étienne France 42055
27 CHU Strasbourg Strasbourg France 67200
28 CHU Toulouse Toulouse France 31059
29 CHU Tours Tours France 37170

Sponsors and Collaborators

  • Assistance Publique Hopitaux De Marseille

Investigators

  • Study Director: Urielle DESALBRES, ASSISTANCE Publique Hôpitaux de Marseille

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Assistance Publique Hopitaux De Marseille
ClinicalTrials.gov Identifier:
NCT02866526
Other Study ID Numbers:
  • 2016-30
First Posted:
Aug 15, 2016
Last Update Posted:
Feb 15, 2018
Last Verified:
Jan 1, 2018
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Assistance Publique Hopitaux De Marseille
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 15, 2018